Home » USA Broker Ratings » Alkermes plc – Consenus Indicates Potential 18.5% Upside

Alkermes plc – Consenus Indicates Potential 18.5% Upside

Alkermes plc found using ticker (ALKS) have now 11 analysts in total covering the stock. The consensus rating is ‘Hold’. The target price ranges between 33 and 20 calculating the mean target price we have 24.73. With the stocks previous close at 20.87 this indicates there is a potential upside of 18.5%. The day 50 moving average is 20.45 while the 200 day moving average is 21.06. The company has a market capitalisation of $3,324m. You can visit the company’s website by visiting: http://www.alkermes.com

Alkermes plc, a biopharmaceutical company, researches, develops, and commercializes pharmaceutical products to address unmet medical needs of patients in various therapeutic areas in the United States, Ireland, and internationally. The company’s marketed products include ARISTADA (aripiprazole lauroxil), an extended-release intramuscular injectable suspension for the treatment of schizophrenia; VIVITROL (naltrexone for extended-release injectable suspension) for the treatment of alcohol and opioid dependence; RISPERDAL CONSTA for the treatment of schizophrenia and bipolar I disorder; INVEGA SUSTENNA for the treatment of schizophrenia and schizoaffective disorder; XEPLION, INVEGA TRINZA, and TREVICTA for treating schizophrenia; and AMPYRA (dalfampridine)/FAMPYRA (fampridine) to enhance walking in adults with multiple sclerosis (MS) who have walking disability. It is also developing BIIB098, a monomethyl fumarate, which is in Phase III clinical trials to treat relapsing forms of MS; ALKS 3831 to treat schizophrenia; ALKS 4230, an engineered fusion protein that is in Phase I clinical trials for cancer immunotherapy; and ALKS 5461 for the treatment of depressive disorders. The company has collaboration agreements with Janssen Pharmaceutica N.V., Janssen Pharmaceutica Inc, and Janssen Pharmaceutica International; license agreement with Acorda Therapeutics, Inc.; and license and collaboration agreement with Biogen Swiss Manufacturing GmbH. It also has a research collaboration with Clovis Oncology, Inc. to evaluate ALKS 4230 in combination with Clovis rucaparib, a PARP inhibitor and lucitanib, an investigational tyrosine kinase inhibitor. It also has a clinical research collaboration with Fred Hutchinson Cancer Research Center for ALKS 4230, Alkermes’ immuno-oncology drug candidate to expand tumor-killing immune cells and to avoid activation of immunosuppressive cells. Alkermes plc was founded in 1987 and is headquartered in Dublin, Ireland.